Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections (Q63338822)

From Wikidata
Jump to navigation Jump to search
clinical trial
edit
Language Label Description Also known as
English
Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections
clinical trial

    Statements

    title
    An Open-label, Randomized Equivalence Trial and Cost-effectiveness Analysis of Ertapenem Versus Other Carbapenems for Treatment of Extended -Spectrum Beta-Lactamase (ESBL)-Producing Gram-negative Bacterial Infections (English)
    0 references
    country
    Thailand
    0 references
    start time
    May 2011
    0 references
    end time
    April 2013
    0 references
    number of participants
    100
    0 references
    research intervention
    ertapenem
    0 references
    meropenem
    0 references
    imipenem/cilastatin
    0 references
    minimum age
    18 year
    0 references

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit
                      Retrieved from "https://www.wikidata.org/w/index.php?title=Q63338822&oldid=2146093559"